255 related articles for article (PubMed ID: 35080036)
1. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
Thomsen SB; Ungaro RC; Allin KH; Elmahdi R; Poulsen G; Andersson M; Colombel JF; Jess T
Aliment Pharmacol Ther; 2022 May; 55(9):1128-1138. PubMed ID: 35080036
[TBL] [Abstract][Full Text] [Related]
2. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
3. Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis.
Ranjan MK; Kumar P; Vuyyuru SK; Kante B; Mundhra SK; Golla R; Virmani S; Sharma R; Sahni P; Das P; Kalaivani M; Upadhyay AD; Makharia G; Kedia S; Ahuja V
J Crohns Colitis; 2024 Feb; 18(2):192-203. PubMed ID: 37584328
[TBL] [Abstract][Full Text] [Related]
4. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
5. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
6. Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis.
Narous M; Nugent Z; Singh H; Bernstein CN
Inflamm Bowel Dis; 2023 Jul; 29(7):1047-1056. PubMed ID: 35929649
[TBL] [Abstract][Full Text] [Related]
7. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
8. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
[TBL] [Abstract][Full Text] [Related]
9. Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.
Barber GE; Hendler S; Choe M; Keyashian K; Lechner S; Limketkai BN; Limsui D
Dig Dis Sci; 2022 Apr; 67(4):1287-1294. PubMed ID: 33755823
[TBL] [Abstract][Full Text] [Related]
10. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
Stournaras E; Qian W; Pappas A; Hong YY; Shawky R; ; Raine T; Parkes M;
Gut; 2021 Apr; 70(4):677-686. PubMed ID: 33004550
[TBL] [Abstract][Full Text] [Related]
12. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
Mahmoud R; Savelkoul EHJ; Mares W; Goetgebuer R; Witteman BJM; de Koning DB; van Tuyl SAC; Minderhoud I; Lutgens MWMD; Akol-Simsek D; van Schaik FDM; Fidder HH; Jansen JM; van Boeckel PGA; Mahmmod N; Horjus-Talabur Horje CS; Römkens TEH; Colombel JF; Hoentjen F; Jharap B; Oldenburg B;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
[TBL] [Abstract][Full Text] [Related]
13. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
Thomsen SB; Allin KH; Burisch J; Jensen CB; Hansen S; Gluud LL; Theede K; Kiszka-Kanowitz M; Nielsen AM; Jess T
United European Gastroenterol J; 2020 Feb; 8(1):68-76. PubMed ID: 32213059
[TBL] [Abstract][Full Text] [Related]
14. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.
Ungaro RC; Limketkai BN; Jensen CB; Yzet C; Allin KH; Agrawal M; Ullman T; Burisch J; Jess T; Colombel JF
Clin Gastroenterol Hepatol; 2020 May; 18(5):1152-1160.e1. PubMed ID: 31419574
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases.
Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Avlund S; Olesen TB; Green A; Hoffmann HJ; Thomsen MK; Thomsen VØ; Nexø BA; Vogel U; Andersen V
Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748864
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of genital warts in inflammatory bowel disease: A Danish registry-based cohort study (1996-2018).
Elmahdi R; Thomsen LT; Iversen AT; Allin KH; Kjaer SK; Jess T
United European Gastroenterol J; 2022 Apr; 10(3):287-295. PubMed ID: 35297191
[TBL] [Abstract][Full Text] [Related]
17. Impact of antitumour necrosis factor therapy on surgery in inflammatory bowel disease: a population-based study.
Hawthorne AB; Arms-Williams B; Cannings-John R; Pollok RCG; Berry A; Harborne P; Trivedi A
BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38777566
[TBL] [Abstract][Full Text] [Related]
18. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.
Lewis JD; Scott FI; Brensinger CM; Roy JA; Osterman MT; Mamtani R; Bewtra M; Chen L; Yun H; Xie F; Curtis JR
Am J Gastroenterol; 2018 Mar; 113(3):405-417. PubMed ID: 29336432
[TBL] [Abstract][Full Text] [Related]
19. Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor.
Meyer A; Taine M; Drouin J; Weill A; Carbonnel F; Dray-Spira R
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1269-1281.e9. PubMed ID: 34298191
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]